[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100580206":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":26,"locations":38,"responsibleParty":112,"collaborators":26,"id":114,"slug":115,"hasResults":116,"nctId":117,"briefTitle":118,"officialTitle":119,"acronym":120,"eligibilityCriteria":121,"healthyVolunteers":116,"sex":122,"minAge":123,"maxAge":124,"enrollmentInfo":125,"targetDuration":26,"studyType":128,"phases":129,"briefSummary":131,"conditions":132,"keywords":136,"overallStatus":67,"whyStopped":26,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":146,"locationsCount":147},{"fullName":5,"class":6},"CERo Therapeutics Holdings, Inc.","INDUSTRY",[8,17],{"label":9,"type":10,"description":11,"interventionNames":12},"Part 1: Single Agent CER-1236","EXPERIMENTAL","AML patient treated with a single dose of CER-1236 monotherapy",[13,14,15,16],"Drug: CER-1236","Drug: Cyclophosphamide","Drug: Fludarabine","Drug: Mesna",{"label":18,"type":10,"description":11,"interventionNames":19},"Part 2: Single Agent CER-1236",[13,14,15,16],[21,27,31,34],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","CER-1236","an autologous chimeric engulfment receptor T-cell",[9,18],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Cyclophosphamide","Lymphodepleting chemotherapy",[9,18],{"type":22,"name":32,"description":29,"armGroupLabels":33,"otherNames":26},"Fludarabine",[9,18],{"type":22,"name":35,"description":36,"armGroupLabels":37,"otherNames":26},"Mesna","Chemoprotectant",[9,18],[39,65,82,96],{"facility":40,"status":41,"city":42,"state":43,"zip":44,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"University of California, Davis Comprehensive Cancer Center","NOT_YET_RECRUITING","Sacramento","California","95817","United States","US",{"type":48,"coordinates":49},"Point",[50,51],-121.4944,38.58157,{"lat":51,"lon":50},[54,59,63],{"name":55,"role":56,"phone":57,"phoneExt":26,"email":58},"Brian Jonas, MD","CONTACT","916-382-6970","bajonas@health.ucdavis.edu",{"name":60,"role":56,"phone":61,"phoneExt":26,"email":62},"Alpha Stem Cell Clinic","916-734-","OCRReferral@health.ucdavis.edu",{"name":55,"role":64,"phone":26,"phoneExt":26,"email":26},"PRINCIPAL_INVESTIGATOR",{"facility":66,"status":67,"city":68,"state":69,"zip":70,"country":45,"countryCode":46,"cosmosGeoPoint":71,"geoPoint":75,"contacts":76},"Colorado Blood Cancer Institute","RECRUITING","Denver","Colorado","80218",{"type":48,"coordinates":72},[73,74],-104.9847,39.73915,{"lat":74,"lon":73},[77,80],{"name":78,"role":56,"phone":26,"phoneExt":26,"email":79},"Maris Michael, MD","PSLMDLCBCINewClinicPatient@HCAHealthcare.com",{"name":81,"role":64,"phone":26,"phoneExt":26,"email":26},"Michael Maris, MD",{"facility":83,"status":67,"city":84,"state":85,"zip":86,"country":45,"countryCode":46,"cosmosGeoPoint":87,"geoPoint":91,"contacts":92},"Sarah Cannon Research Insitute","Nashville","Tennessee","37203",{"type":48,"coordinates":88},[89,90],-86.78444,36.16589,{"lat":90,"lon":89},[93],{"name":94,"role":56,"phone":95,"phoneExt":26,"email":26},"AskSarah Help Line Have Cancer Questions? askSARAH | Sarah Cannon","844-482-4812",{"facility":97,"status":67,"city":98,"state":99,"zip":100,"country":45,"countryCode":46,"cosmosGeoPoint":101,"geoPoint":105,"contacts":106},"The University of Texas MD Anderson Cancer Center","Houston","Texas","77030",{"type":48,"coordinates":102},[103,104],-95.36327,29.76328,{"lat":104,"lon":103},[107,111],{"name":108,"role":56,"phone":109,"phoneExt":26,"email":110},"Abhishek Maiti, MD","713-745-3228","amaiti@mdanderson.org",{"name":108,"role":64,"phone":26,"phoneExt":26,"email":26},{"type":113,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR","100580206","phase-1-cer-1236-in-patients-with-acute-myeloid-leukemia-aml-myelodysplastic-syndrome-mds-and-myelofibrosis-mf-100580206",false,"NCT06834282","CER-1236 in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myelofibrosis (MF)","Phase 1\u002F1b First-in-human Study of Autologous Chimeric Engulfment Receptor T-Cell CER-1236 in Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, and Myelofibrosis (CertainT-1)","CertainT-1","Inclusion Criteria:\n\n* Patients need to have a confirmed diagnosis of de novo or secondary AML, or myelodysplastic syndrome (MDS)\u002FAML with 10% to 19% blasts, per the International Consensus Classification 2022 or the WHO 2022 classification.\n* Absolute lymphocyte count \\>0.3 x 109\u002FL prior to apheresis.\n* Eastern cooperative oncology group (ECOG) performance status 0 to 1.\n\nExclusion Criteria:\n\n* Prior therapy with a permanently integrated, genetically modified cell product.\n* No measurable leukemia on the screening bone marrow evaluation prior to any bridging therapy.\n* Active autoimmune disease or history of autoimmune disease requiring treatment within the prior 2 years. Patients with history of autoimmune thyroiditis or type 1 diabetes well controlled on replacement regimen are eligible.\n* A known hypersensitivity or severe allergy to fludarabine, cyclophosphamide, or study drug components or diluents.\n* Any other medical, psychological, or social condition that may interfere with study participation or compliance, or compromise patient safety in the opinion of the physician.\n* Primary immunodeficiency disorder.","ALL","18 Years","85 Years",{"count":126,"type":127},18,"ESTIMATED","INTERVENTIONAL",[130],"PHASE1","This is a first in human, multi center, open label, phase 1\u002F1b study to evaluate the safety and preliminary efficacy of CER-1236 in patients with relapsed\u002Frefractory (R\u002FR), measurable residual disease (MRD) positive acute myeloid leukemia (AML), or TP53mut disease.",[133,134,135],"AML","Acute Myeloid Leukemia","Refractory Acute Myeloid Leukemia",[137],"Relapsed Acute Myeloid Leukemia","2026-03-23",{"date":140,"type":141},"2026-03-27","ACTUAL",{"date":143,"type":141},"2025-04-07",{"date":145,"type":127},"2029-12-31",{"name":5,"class":6},4]